PRMT5 and neoplasm: The dysregulation of both PKMTs (such as EZH2, G9A, SETD7, SETD8, SYMD2 and SYMD3) and PRMTs (such as PRMT1, PRMT3, PRMT5 and PRMT6) in tumours has been shown to promote drug resistance in various ways such as by CSC renewal, activation of key signalling pathways like the Wnt/Notch pathway and through cell cycle progression.